Global Lansoprazole Market

Lansoprazole Comprehensive Study by Type (Capsules, OD Tablet, Injection), Application (Male, Female), Distribution Channel (Hospital pharmacies, Online pharmacies, Retail pharmacies, Drug stores), Route of administration (Oral, Intravenous) Players and Region - Global Market Outlook to 2030

Lansoprazole Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Lansoprazole is a proton pump inhibitor drug, which prevents the stomach from producing gastric acid to facilitate treatment of various gastric disorders. Proton pump inhibitors work on the mechanism of action, where these act by inhibiting the proton pump, which is the pivotal area for secretion of H+ ions in the gastric lumen. Proton pump inhibitors form a covalent bond with proton pump, deactivating it, leading to lack of H+ ions secretion in the gastric lumen, thereby inhibiting the production of gastric acid. Lansoprazole is different from other drug classes available for treatment of gastroesophageal reflux disease such as antacids, which act by neutralizing the acid secreted in the stomach

Highlights from Lansoprazole Market Study
AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The key Players profiled in the report are Takeda Pharmaceutical (Japan), Teva Pharms (Israel), Sandoz (Germany), GSK (United Kingdom), Dr. Reddy's (India), Pfizer (United States), Mylan (United States), Cisen Pharmaceutical (China), Lepu Pharmaceuticals (China) and Nang Kuang Pharmaceutical (Taiwan). Additionally, other players that are part of this comprehensive study are Luoxin Biotechnology, Beijing Honglin Pharma., Suzhou YUSHI Pharmaceutical Co., Changzhou Siyao Pharmaceuticals and Youcare Pharmaceutical Group.

Geographic Breakdown and Segment Analysis
The Global Lansoprazole market presents a comprehensive analysis of the Lansoprazole market by product type (Capsules, OD Tablet and Injection), by end-user/application (Male and Female), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Lansoprazole industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Lansoprazole market

Analyst at AMA have segmented the market study of Global Lansoprazole market by Type, Application and Region.

Influencing Trend:
Rise in prescription base for sustained release lansoprazole

Market Growth Drivers:
Increase in incidence of gastroesophageal reflux disease (GERD), gastric ulcers, duodenal ulcers, and other gastric diseases. Along with other factors like rise in demand for proton pump inhibitors and ongoing clinical trials for the evaluation of new formulations of lansoprazole aimed at increasing the efficiency of the drug which are expected to drive the global lansoprazole market

Challenges:
Side effects can associated with the over dosage of medicine

Restraints:
Introduction of new drug classes in the market for the treatment of gastric diseases

Opportunities:
Increase in number of manufacturers in the global market offering lansoprazole in capsule formulations

Market Developments Activities:

In February 2021,Dr Reddy’s Laboratories announced the launch of Lansoprazole DR orally disintegrating tablets, a therapeutic equivalent generic version of Prevacid SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the US Food and Drug Administration (USFDA).



The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. Players are anticipated to focus on the development of new medication, which is likely to encourage the growth of the global market throughout the forecast period

Key Target Audience
Medline manufacturer, Hospitals, Pharmacies, Research Firm, Laboratories and Others

Report Objectives / Segmentation Covered

By Type
  • Capsules
  • OD Tablet
  • Injection
By Application
  • Male
  • Female
By Distribution Channel
  • Hospital pharmacies
  • Online pharmacies
  • Retail pharmacies
  • Drug stores

By Route of administration
  • Oral
  • Intravenous

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in incidence of gastroesophageal reflux disease (GERD), gastric ulcers, duodenal ulcers, and other gastric diseases. Along with other factors like rise in demand for proton pump inhibitors and ongoing clinical trials for the evaluation of new formulations of lansoprazole aimed at increasing the efficiency of the drug which are expected to drive the global lansoprazole market
    • 3.3. Market Challenges
      • 3.3.1. Side effects can associated with the over dosage of medicine
    • 3.4. Market Trends
      • 3.4.1. Rise in prescription base for sustained release lansoprazole
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lansoprazole, by Type, Application, Distribution Channel, Route of administration and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lansoprazole (Value)
      • 5.2.1. Global Lansoprazole by: Type (Value)
        • 5.2.1.1. Capsules
        • 5.2.1.2. OD Tablet
        • 5.2.1.3. Injection
      • 5.2.2. Global Lansoprazole by: Application (Value)
        • 5.2.2.1. Male
        • 5.2.2.2. Female
      • 5.2.3. Global Lansoprazole by: Distribution Channel (Value)
        • 5.2.3.1. Hospital pharmacies
        • 5.2.3.2. Online pharmacies
        • 5.2.3.3. Retail pharmacies
        • 5.2.3.4. Drug stores
      • 5.2.4. Global Lansoprazole by: Route of administration (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Intravenous
      • 5.2.5. Global Lansoprazole Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Lansoprazole: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Takeda Pharmaceutical (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva Pharms (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sandoz (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GSK (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Dr. Reddy's (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cisen Pharmaceutical (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lepu Pharmaceuticals (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Nang Kuang Pharmaceutical (Taiwan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Lansoprazole Sale, by Type, Application, Distribution Channel, Route of administration and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lansoprazole (Value)
      • 7.2.1. Global Lansoprazole by: Type (Value)
        • 7.2.1.1. Capsules
        • 7.2.1.2. OD Tablet
        • 7.2.1.3. Injection
      • 7.2.2. Global Lansoprazole by: Application (Value)
        • 7.2.2.1. Male
        • 7.2.2.2. Female
      • 7.2.3. Global Lansoprazole by: Distribution Channel (Value)
        • 7.2.3.1. Hospital pharmacies
        • 7.2.3.2. Online pharmacies
        • 7.2.3.3. Retail pharmacies
        • 7.2.3.4. Drug stores
      • 7.2.4. Global Lansoprazole by: Route of administration (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Intravenous
      • 7.2.5. Global Lansoprazole Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lansoprazole: by Type(USD Million)
  • Table 2. Lansoprazole Capsules , by Region USD Million (2018-2023)
  • Table 3. Lansoprazole OD Tablet , by Region USD Million (2018-2023)
  • Table 4. Lansoprazole Injection , by Region USD Million (2018-2023)
  • Table 5. Lansoprazole: by Application(USD Million)
  • Table 6. Lansoprazole Male , by Region USD Million (2018-2023)
  • Table 7. Lansoprazole Female , by Region USD Million (2018-2023)
  • Table 8. Lansoprazole: by Distribution Channel(USD Million)
  • Table 9. Lansoprazole Hospital pharmacies , by Region USD Million (2018-2023)
  • Table 10. Lansoprazole Online pharmacies , by Region USD Million (2018-2023)
  • Table 11. Lansoprazole Retail pharmacies , by Region USD Million (2018-2023)
  • Table 12. Lansoprazole Drug stores , by Region USD Million (2018-2023)
  • Table 13. Lansoprazole: by Route of administration(USD Million)
  • Table 14. Lansoprazole Oral , by Region USD Million (2018-2023)
  • Table 15. Lansoprazole Intravenous , by Region USD Million (2018-2023)
  • Table 16. South America Lansoprazole, by Country USD Million (2018-2023)
  • Table 17. South America Lansoprazole, by Type USD Million (2018-2023)
  • Table 18. South America Lansoprazole, by Application USD Million (2018-2023)
  • Table 19. South America Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 20. South America Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 21. Brazil Lansoprazole, by Type USD Million (2018-2023)
  • Table 22. Brazil Lansoprazole, by Application USD Million (2018-2023)
  • Table 23. Brazil Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 24. Brazil Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 25. Argentina Lansoprazole, by Type USD Million (2018-2023)
  • Table 26. Argentina Lansoprazole, by Application USD Million (2018-2023)
  • Table 27. Argentina Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 28. Argentina Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 29. Rest of South America Lansoprazole, by Type USD Million (2018-2023)
  • Table 30. Rest of South America Lansoprazole, by Application USD Million (2018-2023)
  • Table 31. Rest of South America Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 32. Rest of South America Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 33. Asia Pacific Lansoprazole, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Lansoprazole, by Type USD Million (2018-2023)
  • Table 35. Asia Pacific Lansoprazole, by Application USD Million (2018-2023)
  • Table 36. Asia Pacific Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 37. Asia Pacific Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 38. China Lansoprazole, by Type USD Million (2018-2023)
  • Table 39. China Lansoprazole, by Application USD Million (2018-2023)
  • Table 40. China Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 41. China Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 42. Japan Lansoprazole, by Type USD Million (2018-2023)
  • Table 43. Japan Lansoprazole, by Application USD Million (2018-2023)
  • Table 44. Japan Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 45. Japan Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 46. India Lansoprazole, by Type USD Million (2018-2023)
  • Table 47. India Lansoprazole, by Application USD Million (2018-2023)
  • Table 48. India Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 49. India Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 50. South Korea Lansoprazole, by Type USD Million (2018-2023)
  • Table 51. South Korea Lansoprazole, by Application USD Million (2018-2023)
  • Table 52. South Korea Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 53. South Korea Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 54. Taiwan Lansoprazole, by Type USD Million (2018-2023)
  • Table 55. Taiwan Lansoprazole, by Application USD Million (2018-2023)
  • Table 56. Taiwan Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 57. Taiwan Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 58. Australia Lansoprazole, by Type USD Million (2018-2023)
  • Table 59. Australia Lansoprazole, by Application USD Million (2018-2023)
  • Table 60. Australia Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 61. Australia Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Lansoprazole, by Type USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Lansoprazole, by Application USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 66. Europe Lansoprazole, by Country USD Million (2018-2023)
  • Table 67. Europe Lansoprazole, by Type USD Million (2018-2023)
  • Table 68. Europe Lansoprazole, by Application USD Million (2018-2023)
  • Table 69. Europe Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 70. Europe Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 71. Germany Lansoprazole, by Type USD Million (2018-2023)
  • Table 72. Germany Lansoprazole, by Application USD Million (2018-2023)
  • Table 73. Germany Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 74. Germany Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 75. France Lansoprazole, by Type USD Million (2018-2023)
  • Table 76. France Lansoprazole, by Application USD Million (2018-2023)
  • Table 77. France Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 78. France Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 79. Italy Lansoprazole, by Type USD Million (2018-2023)
  • Table 80. Italy Lansoprazole, by Application USD Million (2018-2023)
  • Table 81. Italy Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 82. Italy Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 83. United Kingdom Lansoprazole, by Type USD Million (2018-2023)
  • Table 84. United Kingdom Lansoprazole, by Application USD Million (2018-2023)
  • Table 85. United Kingdom Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 86. United Kingdom Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 87. Netherlands Lansoprazole, by Type USD Million (2018-2023)
  • Table 88. Netherlands Lansoprazole, by Application USD Million (2018-2023)
  • Table 89. Netherlands Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 90. Netherlands Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 91. Rest of Europe Lansoprazole, by Type USD Million (2018-2023)
  • Table 92. Rest of Europe Lansoprazole, by Application USD Million (2018-2023)
  • Table 93. Rest of Europe Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 94. Rest of Europe Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 95. MEA Lansoprazole, by Country USD Million (2018-2023)
  • Table 96. MEA Lansoprazole, by Type USD Million (2018-2023)
  • Table 97. MEA Lansoprazole, by Application USD Million (2018-2023)
  • Table 98. MEA Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 99. MEA Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 100. Middle East Lansoprazole, by Type USD Million (2018-2023)
  • Table 101. Middle East Lansoprazole, by Application USD Million (2018-2023)
  • Table 102. Middle East Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 103. Middle East Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 104. Africa Lansoprazole, by Type USD Million (2018-2023)
  • Table 105. Africa Lansoprazole, by Application USD Million (2018-2023)
  • Table 106. Africa Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 107. Africa Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 108. North America Lansoprazole, by Country USD Million (2018-2023)
  • Table 109. North America Lansoprazole, by Type USD Million (2018-2023)
  • Table 110. North America Lansoprazole, by Application USD Million (2018-2023)
  • Table 111. North America Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 112. North America Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 113. United States Lansoprazole, by Type USD Million (2018-2023)
  • Table 114. United States Lansoprazole, by Application USD Million (2018-2023)
  • Table 115. United States Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 116. United States Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 117. Canada Lansoprazole, by Type USD Million (2018-2023)
  • Table 118. Canada Lansoprazole, by Application USD Million (2018-2023)
  • Table 119. Canada Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 120. Canada Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 121. Mexico Lansoprazole, by Type USD Million (2018-2023)
  • Table 122. Mexico Lansoprazole, by Application USD Million (2018-2023)
  • Table 123. Mexico Lansoprazole, by Distribution Channel USD Million (2018-2023)
  • Table 124. Mexico Lansoprazole, by Route of administration USD Million (2018-2023)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Lansoprazole: by Type(USD Million)
  • Table 136. Lansoprazole Capsules , by Region USD Million (2025-2030)
  • Table 137. Lansoprazole OD Tablet , by Region USD Million (2025-2030)
  • Table 138. Lansoprazole Injection , by Region USD Million (2025-2030)
  • Table 139. Lansoprazole: by Application(USD Million)
  • Table 140. Lansoprazole Male , by Region USD Million (2025-2030)
  • Table 141. Lansoprazole Female , by Region USD Million (2025-2030)
  • Table 142. Lansoprazole: by Distribution Channel(USD Million)
  • Table 143. Lansoprazole Hospital pharmacies , by Region USD Million (2025-2030)
  • Table 144. Lansoprazole Online pharmacies , by Region USD Million (2025-2030)
  • Table 145. Lansoprazole Retail pharmacies , by Region USD Million (2025-2030)
  • Table 146. Lansoprazole Drug stores , by Region USD Million (2025-2030)
  • Table 147. Lansoprazole: by Route of administration(USD Million)
  • Table 148. Lansoprazole Oral , by Region USD Million (2025-2030)
  • Table 149. Lansoprazole Intravenous , by Region USD Million (2025-2030)
  • Table 150. South America Lansoprazole, by Country USD Million (2025-2030)
  • Table 151. South America Lansoprazole, by Type USD Million (2025-2030)
  • Table 152. South America Lansoprazole, by Application USD Million (2025-2030)
  • Table 153. South America Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 154. South America Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 155. Brazil Lansoprazole, by Type USD Million (2025-2030)
  • Table 156. Brazil Lansoprazole, by Application USD Million (2025-2030)
  • Table 157. Brazil Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 158. Brazil Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 159. Argentina Lansoprazole, by Type USD Million (2025-2030)
  • Table 160. Argentina Lansoprazole, by Application USD Million (2025-2030)
  • Table 161. Argentina Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 162. Argentina Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 163. Rest of South America Lansoprazole, by Type USD Million (2025-2030)
  • Table 164. Rest of South America Lansoprazole, by Application USD Million (2025-2030)
  • Table 165. Rest of South America Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 166. Rest of South America Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 167. Asia Pacific Lansoprazole, by Country USD Million (2025-2030)
  • Table 168. Asia Pacific Lansoprazole, by Type USD Million (2025-2030)
  • Table 169. Asia Pacific Lansoprazole, by Application USD Million (2025-2030)
  • Table 170. Asia Pacific Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 171. Asia Pacific Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 172. China Lansoprazole, by Type USD Million (2025-2030)
  • Table 173. China Lansoprazole, by Application USD Million (2025-2030)
  • Table 174. China Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 175. China Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 176. Japan Lansoprazole, by Type USD Million (2025-2030)
  • Table 177. Japan Lansoprazole, by Application USD Million (2025-2030)
  • Table 178. Japan Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 179. Japan Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 180. India Lansoprazole, by Type USD Million (2025-2030)
  • Table 181. India Lansoprazole, by Application USD Million (2025-2030)
  • Table 182. India Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 183. India Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 184. South Korea Lansoprazole, by Type USD Million (2025-2030)
  • Table 185. South Korea Lansoprazole, by Application USD Million (2025-2030)
  • Table 186. South Korea Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 187. South Korea Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 188. Taiwan Lansoprazole, by Type USD Million (2025-2030)
  • Table 189. Taiwan Lansoprazole, by Application USD Million (2025-2030)
  • Table 190. Taiwan Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 191. Taiwan Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 192. Australia Lansoprazole, by Type USD Million (2025-2030)
  • Table 193. Australia Lansoprazole, by Application USD Million (2025-2030)
  • Table 194. Australia Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 195. Australia Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific Lansoprazole, by Type USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific Lansoprazole, by Application USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 200. Europe Lansoprazole, by Country USD Million (2025-2030)
  • Table 201. Europe Lansoprazole, by Type USD Million (2025-2030)
  • Table 202. Europe Lansoprazole, by Application USD Million (2025-2030)
  • Table 203. Europe Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 204. Europe Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 205. Germany Lansoprazole, by Type USD Million (2025-2030)
  • Table 206. Germany Lansoprazole, by Application USD Million (2025-2030)
  • Table 207. Germany Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 208. Germany Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 209. France Lansoprazole, by Type USD Million (2025-2030)
  • Table 210. France Lansoprazole, by Application USD Million (2025-2030)
  • Table 211. France Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 212. France Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 213. Italy Lansoprazole, by Type USD Million (2025-2030)
  • Table 214. Italy Lansoprazole, by Application USD Million (2025-2030)
  • Table 215. Italy Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 216. Italy Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 217. United Kingdom Lansoprazole, by Type USD Million (2025-2030)
  • Table 218. United Kingdom Lansoprazole, by Application USD Million (2025-2030)
  • Table 219. United Kingdom Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 220. United Kingdom Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 221. Netherlands Lansoprazole, by Type USD Million (2025-2030)
  • Table 222. Netherlands Lansoprazole, by Application USD Million (2025-2030)
  • Table 223. Netherlands Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 224. Netherlands Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 225. Rest of Europe Lansoprazole, by Type USD Million (2025-2030)
  • Table 226. Rest of Europe Lansoprazole, by Application USD Million (2025-2030)
  • Table 227. Rest of Europe Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 228. Rest of Europe Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 229. MEA Lansoprazole, by Country USD Million (2025-2030)
  • Table 230. MEA Lansoprazole, by Type USD Million (2025-2030)
  • Table 231. MEA Lansoprazole, by Application USD Million (2025-2030)
  • Table 232. MEA Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 233. MEA Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 234. Middle East Lansoprazole, by Type USD Million (2025-2030)
  • Table 235. Middle East Lansoprazole, by Application USD Million (2025-2030)
  • Table 236. Middle East Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 237. Middle East Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 238. Africa Lansoprazole, by Type USD Million (2025-2030)
  • Table 239. Africa Lansoprazole, by Application USD Million (2025-2030)
  • Table 240. Africa Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 241. Africa Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 242. North America Lansoprazole, by Country USD Million (2025-2030)
  • Table 243. North America Lansoprazole, by Type USD Million (2025-2030)
  • Table 244. North America Lansoprazole, by Application USD Million (2025-2030)
  • Table 245. North America Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 246. North America Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 247. United States Lansoprazole, by Type USD Million (2025-2030)
  • Table 248. United States Lansoprazole, by Application USD Million (2025-2030)
  • Table 249. United States Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 250. United States Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 251. Canada Lansoprazole, by Type USD Million (2025-2030)
  • Table 252. Canada Lansoprazole, by Application USD Million (2025-2030)
  • Table 253. Canada Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 254. Canada Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 255. Mexico Lansoprazole, by Type USD Million (2025-2030)
  • Table 256. Mexico Lansoprazole, by Application USD Million (2025-2030)
  • Table 257. Mexico Lansoprazole, by Distribution Channel USD Million (2025-2030)
  • Table 258. Mexico Lansoprazole, by Route of administration USD Million (2025-2030)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lansoprazole: by Type USD Million (2018-2023)
  • Figure 5. Global Lansoprazole: by Application USD Million (2018-2023)
  • Figure 6. Global Lansoprazole: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Lansoprazole: by Route of administration USD Million (2018-2023)
  • Figure 8. South America Lansoprazole Share (%), by Country
  • Figure 9. Asia Pacific Lansoprazole Share (%), by Country
  • Figure 10. Europe Lansoprazole Share (%), by Country
  • Figure 11. MEA Lansoprazole Share (%), by Country
  • Figure 12. North America Lansoprazole Share (%), by Country
  • Figure 13. Global Lansoprazole share by Players 2023 (%)
  • Figure 14. Global Lansoprazole share by Players (Top 3) 2023(%)
  • Figure 15. Global Lansoprazole share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Takeda Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 18. Takeda Pharmaceutical (Japan) Revenue: by Geography 2023
  • Figure 19. Teva Pharms (Israel) Revenue, Net Income and Gross profit
  • Figure 20. Teva Pharms (Israel) Revenue: by Geography 2023
  • Figure 21. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Sandoz (Germany) Revenue: by Geography 2023
  • Figure 23. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GSK (United Kingdom) Revenue: by Geography 2023
  • Figure 25. Dr. Reddy's (India) Revenue, Net Income and Gross profit
  • Figure 26. Dr. Reddy's (India) Revenue: by Geography 2023
  • Figure 27. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer (United States) Revenue: by Geography 2023
  • Figure 29. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mylan (United States) Revenue: by Geography 2023
  • Figure 31. Cisen Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 32. Cisen Pharmaceutical (China) Revenue: by Geography 2023
  • Figure 33. Lepu Pharmaceuticals (China) Revenue, Net Income and Gross profit
  • Figure 34. Lepu Pharmaceuticals (China) Revenue: by Geography 2023
  • Figure 35. Nang Kuang Pharmaceutical (Taiwan) Revenue, Net Income and Gross profit
  • Figure 36. Nang Kuang Pharmaceutical (Taiwan) Revenue: by Geography 2023
  • Figure 37. Global Lansoprazole: by Type USD Million (2025-2030)
  • Figure 38. Global Lansoprazole: by Application USD Million (2025-2030)
  • Figure 39. Global Lansoprazole: by Distribution Channel USD Million (2025-2030)
  • Figure 40. Global Lansoprazole: by Route of administration USD Million (2025-2030)
  • Figure 41. South America Lansoprazole Share (%), by Country
  • Figure 42. Asia Pacific Lansoprazole Share (%), by Country
  • Figure 43. Europe Lansoprazole Share (%), by Country
  • Figure 44. MEA Lansoprazole Share (%), by Country
  • Figure 45. North America Lansoprazole Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Takeda Pharmaceutical (Japan)
  • Teva Pharms (Israel)
  • Sandoz (Germany)
  • GSK (United Kingdom)
  • Dr. Reddy's (India)
  • Pfizer (United States)
  • Mylan (United States)
  • Cisen Pharmaceutical (China)
  • Lepu Pharmaceuticals (China)
  • Nang Kuang Pharmaceutical (Taiwan)
Additional players considered in the study are as follows:
Luoxin Biotechnology , Beijing Honglin Pharma. , Suzhou YUSHI Pharmaceutical Co. , Changzhou Siyao Pharmaceuticals , Youcare Pharmaceutical Group
Select User Access Type

Key Highlights of Report


Mar 2024 233 Pages 52 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lansoprazole Market Quantitative research analysis
Global Lansoprazole Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2030
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • Side effects can associated with the over dosage of medicine

Know More About Global Lansoprazole Market Report?

Have a Query? Click Here

Other Related Reports

Hair Loss and Growth Devices Comprehensive Study by Type (Lasers, LED, Others), Application (Homecare, Hair Loss Treatment Clinic), Gender (Men, Women) Players and Region - Global Market Outlook to 2...
$ 3500
Hormonal Contraceptive Comprehensive Study by Type (Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, Transdermal Patches), Formulations (Combined Meth...
$ 3750
Lectins Comprehensive Study by Type (Above 90%, Above 95%, Above 99%, Others), Application (Bioscience Research Institutions, Biopharmaceutical Companies, Hospitals, Others), End-Use Industry (Health...
$ 3350
Viral Molecular Diagnostics Comprehensive Study by Type (Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV)), Application (Infectious Dis...
$ 3750
Simple Island Dressings Comprehensive Study by Type (Traditional Wound Dressings, Advanced Wound Dressings), Application (Wet Wound, Dry Wound), Distribution Channel (Online, Offline), Size (2"x2" (...
$ 3450
Teicoplanin Comprehensive Study by Type (200 mg, 400 mg), Application (Bone and Joint Infection, Severe Skin and Soft Tissue Infection, Bacteraemia, Others), End-User (Adults, Children) Players and R...
$ 3500